We emphasize the promise of targeting the metabolic–epigenetic axis using rationally designed pharmacological agents (both natural and synthetic), novel gene-based interventions, and combination regimens, particularly in the context of PCa subtypes defined by LKB1 status and associated molecular alterations. This evidence concerns the gene STK11 and posterior cortical atrophy.